|
|
 |
|
Viewing report
|
|
|
|
Ark Therapeutics Group plc (AKT) - Financial and Strategic SWOT Analysis Review
GlobalData, April 2012, Pages: 43
Ark Therapeutics Group plc (AKT) - Financial and Strategic SWOT Analysis Review
Summary
Ark Therapeutics Group plc (Ark Therapeutics) is a UK based specialist healthcare group involved in the discovery, development and commercialization of specialist medicines with focus on vascular disease and cancer. The company’s pipeline product candidates include EG013 for fetal growth restriction, EG011 for refractory angina, EG016 for peripheral vascular disease, Cerepro for malignant glioma, and Trinam for maintaining vascular access grafts. The company operates in the UK and Finland. Ark Therapeutics’ biological manufacturing operations are based in Kuopio, Finland. Ark Therapeutics is headquartered in London, the UK.
The company’s strategic intent focuses on the capitalization of its pipeline of programs in the areas of unmet medical need within vascular disease and cancer. Recently, the United States Patent and Trademark Office (USPTO) issued a notice of allowance for the company with respect to a patent covering the structures of candidate compounds in Ark's Neuropilin-1 receptor (NRP-1) small molecule antagonist programs.
Ark Therapeutics Group plc Key Recent Developments
Mar 13, 2012: Ark Therapeutics Appoints Charles Spicer As Non-Executive Director
Mar 12, 2012: Ark Therapeutics Reports 2011 Results
Feb 08, 2012: Ark Therapeutics Announces Notice Of Allowance Of US Patent For Neuropilin-1 Receptor Small Molecule Antagonists
Aug 24, 2011: Ark Therapeutics Reports H1 2011 Results
Jul 14, 2011: Ark Led Consortium Wins €5.3m EU Framework Programme 7 Grant
This comprehensive SWOT profile of Ark Therapeutics Group plc provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Customers who bought this item also bought
Ark Therapeutics Group plc - Product Pipeline Review - H2 2011
Ark Therapeutics Group plc - Product Pipeline Review - Q2 2011
Ark Therapeutics Group plc - Product Pipeline Review - 2012
GlaxoSmithKline plc (GSK) - Financial and Strategic SWOT Analysis Review
Hikma Pharmaceuticals PLC (HIK) - Financial and Strategic SWOT Analysis Review
Covidien plc (COV) - Financial and Strategic SWOT Analysis Review
Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review
Osiris Therapeutics, Inc. (OSIR) - Financial and Strategic SWOT Analysis Review
Abbott Laboratories (ABT) - Financial and Strategic SWOT Analysis Review
Syneron Medical Ltd. (ELOS) - Financial and Strategic SWOT Analysis Review
|
|
|
|
